U.S. Markets open in 5 hrs 45 mins

(GSK,NVS,SNY)

. Currency in USD
Add to watchlist
Full screen
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Forbes12 hours ago

    Why Gilead Sciences Is Flying High With Kite

    Gilead Sciences has expanded beyond its leading antiviral drug franchises for the treatment of HIV and hepatitis C with the announced acquisition of Kite Pharmaceuticals, giving Gilead a leading edge in cell therapy technology in oncology.

  • Immunize Juno Therapeutics Inc (JUNO) Stock With This Trade
    InvestorPlace16 hours ago

    Immunize Juno Therapeutics Inc (JUNO) Stock With This Trade

    Juno Therapeutics Inc (NASDAQ:JUNO) has a lot going for it off and on the price chart. That doesn’t mean you shouldn’t immunize JUNO stock against the always-real bearish threats. To do that, we’ll explore a fully-hedged, collar-based therapy program. Let me explain.

  • Alnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up
    Zacks17 hours ago

    Alnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up

    Alnylam (ALNY) and partner Sanofi RNAi therapeutic patisiran met its primary efficacy endpoint and all secondary endpoints in the phase III APOLLO study.